Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 2, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Eli Lilly (LLY - Free Report) , Merck (MRK - Free Report) , Pfizer (PFE - Free Report) , Novartis (NVS - Free Report) , AstraZeneca (AZN - Free Report) and J&J (JNJ - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Pharma Stock Roundup: Resuming Covid-16 Testing

Several large drugmakers including Eli Lilly, Merck, Pfizer, Novartis and others released their third-quarter results. While AstraZeneca and J&J prepare to resume U.S. studies on their coronavirus vaccine candidates, a COVID-19 study on Lilly’s antibody candidate was ended.

Recap of the Week’s Most Important Stories

Earnings Update: Pfizer’s results were mixed as it beats estimates for earnings while missing the same for sales. It narrowed its financial outlook for the year as it believes that the pace of recovery from the pandemic has been slower than expected.

Lilly failed to impress with its third-quarter results, missing estimates for both earnings as well as for sales, Key drug, Trulicity’s sales slowed down. It maintained its previously issued earnings guidance.

Merck beat estimates for both earnings and sales. The company tightened its sales guidance for 2020 to reflect continued impact of the COVID-19 pandemic. However, the company raised its guidance for adjusted earnings.

Novartis’ sales missed the Zacks Consensus Estimate while earnings beat the same. Sales in the Innovative Medicines division rose 1% while that in the Sandoz division declined 3%. The company maintained its 2020 sales growth guidance. It raised its core operating profit outlook.

Glaxo beat on third-quarter earnings while slightly missing sales estimates and maintained its adjusted earnings guidance of a decline in the range of 1% to 4% at constant exchange rate year over year

J&J Prepares to Re-Start COVID-19 Vaccine Study: J&J is preparing to resume recruitment in the large pivotal phase III study, ENSEMBLE, on its coronavirus vaccine candidate, JNJ-78436735, which was paused earlier this month. Dosing was paused in the ENSEMBLE study due to an unexplained illness observed in a study participant, which was probed by the ENSEMBLE independent Data Safety Monitoring Board (DSMB). The DSMB has recommended resuming trial recruitment as no clear cause for the illness was determined.

It was also not clear whether the unexpected serious adversity was related to the vaccine shot. Meanwhile, discussions are ongoing with other global regulatory bodies to resume the studies in those countries.

Meanwhile, J&J submitted a supplemental new drug application (sNDA) seeking approval from the FDA for expanded use of its blood thinner, Xarelto in patients with peripheral artery disease (PAD). Xarelto is currently approved to reduce the risk of major cardiovascular events, like heart attack and stroke, in people with chronic PAD. The latest sNDA seeks approval for Xarelto plus aspirin to reduce the risk of major thrombotic vascular events (such as heart attack, stroke and amputation) in patients after lower-extremity revascularization due to symptomatic PAD.

NIH Led Study on Lilly’s Coronavirus Antibody Candidate Ends: The U.S. government’s National Institute of Health (“NIH”) has ended the ACTIV-3 study evaluating Lilly’s monoclonal antibody candidate, bamlanivimab (previously LYCoV555) and Gilead’s remdisivir in hospitalized COVID-19 patients. The study was paused earlier this month following potential safety concerns raised by the independent DSMB. The study was ended as updated data from the same showed that bamlanivimab was unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease.

Lilly said that all other studies on bamlanivimab are ongoing including NIH-led ACTIV-2 study testing recently diagnosed mild to moderate COVID-19 patients as well as Lilly’s phase II BLAZE-1 study and phase III BLAZE-2 study. Last week, Lilly applied to the FDA for Emergency Use Authorization (EUA) of bamlanivimab as a monotherapy for the treatment of higher-risk patients who have been recently diagnosed with mild-to-moderate COVID-19.

Meanwhile, Lilly also signed an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (700 mg) for $375 million if the candidate gets FDA’s EUA. The deal also includes an option for purchase of an additional 650,000 vials through June 2021.

AstraZeneca to Resume COVID-19 Vaccine Study in U.S.: The FDA authorized AstraZeneca to resume late-stage clinical studies on its COVID-19 vaccine candidate, AZD1222, in the United States. Last month, AstraZeneca temporarily paused all its global late-stage studies on AZD1222, which it is developing in partnership with Oxford University, as a patient in U.K. suffered an unspecified illness.

While studies in the UK, Brazil, South Africa and Japan resumed in the weeks thereafter following regulators’ confirmation, the study in the United States remained on hold. The FDA has now reviewed all safety data from the global studies and said it is safe to re-start the U.S. study.

Meanwhile, the FDA granted priority review status to AstraZeneca and its Japan-based partner Daiichi Sankyo’s supplemental biologics license application (sBLA) seeking label expansion of its breast cancer drug Enhertu for HER2-positive metastatic gastric cancer. With a priority review tag, the FDA’s decision is expected in the first quarter of 2021.

Bayer Buys Asklepios to Boost Gene Therapy Presence: Bayer bought small biotech Asklepios BioPharmaceuticals (AskBio), which makes gene therapies across multiple disease areas with high unmet need, thereby strengthening its cell and gene therapy platform. The purchase price was $2 billion upfront and up to $2 billion in success-based milestone payments.

AskBio’s pipeline includes pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases. With the acquisition, Bayer also gains rights to AskBio’s revenue generating contract development and manufacturing organization (CDMO).

Sanofi/Glaxo’s Supply Deal with COVAX:Sanofi and GlaxoSmithKline have agreed to provide 200 million vaccine doses of their adjuvanted, recombinant protein-based COVID-19 vaccine, if approved to the COVAX program. The COVAX program is led by Gavi, CEPI and WHO.

Sanofi also announced an agreement with Merck to conduct a phase II study on its novel investigational candidate THOR-707 in combination with Merck’s Keytruda in patients with various cancers. THOR-707 is currently being evaluated in phase I study for the treatment of solid tumors. Sanofi will sponsor the study while Merck will provide Keytruda.

Meanwhile the European Commission approved Glaxo’s PARP inhibitor, Zejula as first-line monotherapy maintenance treatment for patients with advanced ovarian cancer, regardless of their biomarker status. The approval was based on data from the pivotal phase III PRIMA study. Zejula was approved for the same indication in the United States in April.

The European Commission accepted Glaxo’s regulatory filings, seeking approval of Nucala for three additional eosinophil-driven diseases hypereosinophilic syndrome (HES), chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic granulomatosis with polyangiitis (EGPA). Nucala is presently approved to treat severe eosinophilic asthma in the EU.

FDA Give Priority Tag to Pfizer’s NDA for Eczema Candidate:The FDA accepted and granted priority review status to Pfizer’s NDA seeking approval of its investigational oral JAK inhibitor, abrocitinib, in patients (12 years and older) with moderate-to-severe atopic dermatitis. The FDA’s decision is expected in April 2021. The EMA also accepted the marketing application in the EU for the same indication with a decision expected in the second half of 2021.

Novartis’ New COVID-19 Deal:Novartis announced a deal with Switzerland based Molecular Partners to develop two multi-targeted direct acting antiviral therapeutic candidates, MP0420 and MP0423 designed for potential use against COVID-19. While Molecular Partners will be responsible for conducting phase I studies expected to begin next month, Novartis will be responsible for phase II and III development, manufacturing, distribution and commercialization activities. Per the deal, Novartis will make an upfront payment of CHF 60 million, including equity.

The NYSE ARCA Pharmaceutical Index declined almost 5% in the last five trading sessions.

Large Cap Pharmaceuticals Industry 5YR % Return

Here’s how the eight major stocks performed in the last five trading sessions.

In the last five trading sessions, all stocks declined with Novartis recording the maximum decrease (7.5%).

In the past six months, all stocks have declined with Lilly declining the most (13.7%).

(See the last pharma stock roundup here: J&J’s Q3 Earnings, Pause on Coronavirus Studies & Other Updates)

What's Next in the Pharma World?

Watch out for pipeline and regulatory updates next week along with earnings releases of Bayer and AstraZeneca.

Have You Seen Zacks’ 2020 Election Stock Report?

The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.

The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.

Check out Zacks’ 2020 Election Stock Report >>

Join us on Facbook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.